Approval · Notice of Compliance 37003 · 2026
NEXIUM: Notice of Compliance 37003
Issued February 27, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37003
- Date
- February 27, 2026
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Removal of package insert. Update to package labels
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NEXIUM | Not yet assigned | — |
Medicinal ingredients
- ESOMEPRAZOLE MAGNESIUM TRIHYDRATE 10 MG per SACHET
- ESOMEPRAZOLE MAGNESIUM TRIHYDRATE 20 MG per TAB
- ESOMEPRAZOLE MAGNESIUM TRIHYDRATE 40 MG per TAB